Co-Authors
This is a "connection" page, showing publications co-authored by Simona Di Giambenedetto and Alberto Borghetti.
Connection Strength
7.490
-
COVID-19 diagnosis does not rule out other concomitant diseases. Eur J Clin Invest. 2020 Jun; 50(6):e13241.
Score: 0.880
-
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019 04 01; 74(4):1035-1043.
Score: 0.816
-
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019 Jan 17; 19(1):59.
Score: 0.805
-
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018 Mar 24.
Score: 0.760
-
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. Diagnostics (Basel). 2021 Jun 24; 11(7).
Score: 0.238
-
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. Infez Med. 2021 Mar 01; 29(1):54-64.
Score: 0.233
-
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy. Clin Microbiol Infect. 2020 Dec 02.
Score: 0.229
-
Still Much to Learn About the Diagnostic Role of SARS-CoV-2 Antibody Detection. Clin Infect Dis. 2020 11 19; 71(16):2299-2300.
Score: 0.229
-
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic. HIV Med. 2021 01; 22(1):e3-e4.
Score: 0.225
-
SARS-CoV-2 infection in a highly experienced person living with HIV. AIDS. 2020 07 01; 34(8):1257-1258.
Score: 0.223
-
Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020 10; 92(10):1787-1788.
Score: 0.222
-
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive. J Infect. 2021 01; 82(1):159-198.
Score: 0.221
-
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019 Dec; 54(6):728-734.
Score: 0.210
-
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019 Sep 03; 1-7.
Score: 0.210
-
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 08 01; 74(8):2470-2472.
Score: 0.209
-
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 05 01; 74(5):1461-1463.
Score: 0.205
-
Liver fibrosis is associated with cognitive impairment in people living with HIV. Infection. 2019 Aug; 47(4):589-593.
Score: 0.202
-
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. Infez Med. 2018 Dec 01; 26(4):336-340.
Score: 0.199
-
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. J Clin Virol. 2018 06; 103:57-62.
Score: 0.190
-
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. HIV Med. 2018 07; 19(6):369-375.
Score: 0.188
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.178
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
Score: 0.176
-
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017 Oct; 29(5):299-307.
Score: 0.174
-
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients. Infez Med. 2021 Mar 01; 29(1):163-164.
Score: 0.058
-
People Living with HIV in the COVID-19 Era: A Case Report. AIDS Res Hum Retroviruses. 2021 04; 37(4):253-254.
Score: 0.056
-
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug; 56(2):106017.
Score: 0.055
-
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
Score: 0.048
-
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infect Dis. 2018 Jun; 5(6):ofy113.
Score: 0.048